Found: 17
Select item for more details and to access through your institution.
Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 151, doi. 10.2147/BTT.S431818
- By:
- Publication type:
- Article
The Effect of Two Years of Secukinumab Treatment on Bone Metabolism in Patients with Radiographic Axial Spondyloarthritis: Results from Daily Clinical Practice.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 161, doi. 10.2147/BTT.S434318
- By:
- Publication type:
- Article
Hypoxia Inducible Factor-1α Through ROS/NLRP3 Pathway Regulates the Mechanism of Acute Ischemic Stroke Microglia Scorching Mechanism.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 167, doi. 10.2147/BTT.S444714
- By:
- Publication type:
- Article
Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 129, doi. 10.2147/BTT.S425693
- By:
- Publication type:
- Article
Serum LINC00152 and UCA1 in HCV-Induced Hepatocellular Carcinoma: Clinical Significance and Prognostic Value.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 137, doi. 10.2147/BTT.S433872
- By:
- Publication type:
- Article
Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 113, doi. 10.2147/BTT.S426392
- By:
- Publication type:
- Article
Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 61, doi. 10.2147/BTT.S395817
- By:
- Publication type:
- Article
New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 69, doi. 10.2147/BTT.S405080
- By:
- Publication type:
- Article
Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 85, doi. 10.2147/BTT.S404421
- By:
- Publication type:
- Article
Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Elevated Serum Vinculin in Patients with HBV/HCV-Associated Liver Cirrhosis and Hepatocellular Carcinoma: A Pilot Study.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 23, doi. 10.2147/BTT.S405500
- By:
- Publication type:
- Article
Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 33, doi. 10.2147/BTT.S401289
- By:
- Publication type:
- Article
Critical Response: "Does the Mutation of Cancer Driver Genes IDH1/2 and CD204 Influence Cancer Metabolism and Tumor Associated Macrophage Recruitment in Tumor Microenvironment" [Letter].
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 41, doi. 10.2147/BTT.S410506
- By:
- Publication type:
- Article
Demonstration of Safety in Wild Type Mice of npFOXF1, a Novel Nanoparticle-Based Gene Therapy for Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 43, doi. 10.2147/BTT.S400006
- By:
- Publication type:
- Article
The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 15, doi. 10.2147/BTT.S394556
- By:
- Publication type:
- Article
Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 1, doi. 10.2147/BTT.S389021
- By:
- Publication type:
- Article
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis.
- Published in:
- Biologics: Targets & Therapy, 2023, v. 17, p. 11, doi. 10.2147/BTT.S394843
- By:
- Publication type:
- Article